PressMarch 31, 2023 Apex Labs Meets Endpoints in First-of-its-Kind Take Home Microdose Psilocybin Clinical Trial
PressMarch 31, 2023 BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development Article
PressMarch 31, 2023 PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease
PressMarch 31, 2023 NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression
PressMarch 29, 2023 PSYC’s CEO to Moderate Panel at Film Screening for ESPN’s Upcoming Documentary, “Peace of Mind”
PressMarch 29, 2023 Mindset Pharma CEO, James Lanthier, Issues Letter to Shareholders Discussing Expansion of Drug Discovery Efforts into Novel Non-Hallucinogenic Therapeutics
PressMarch 29, 2023 Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
PressMarch 27, 2023 Reunion Neuroscience Abstract Accepted for Poster Presentation at 2023 ASCP Annual Meeting
PressMarch 27, 2023 Numinus Launches the Practitioner Certification Pathway – a Complete Psychedelic-Assisted Therapy Training Program
PressMarch 24, 2023 FSD Pharma Inc. Subsidiary Receives Official Approval to Move Forward with Phase 1 Clinical Trial
PressMarch 24, 2023 atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
PressMarch 23, 2023 Promise of BetterLife’s Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress Article
PressMarch 23, 2023 Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of Alabama at Birmingham
PressMarch 23, 2023 Numinus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023
PressMarch 21, 2023 Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023
PressMarch 21, 2023 Diamond Therapeutics Announces FDA-authorized Clinical Trial of Low-Dose Psilocybin in Collaboration with University of Alabama at Birmingham
PressMarch 21, 2023 First Patient Dosed in Europe in Clairvoyant’s Phase 2b Clinical Trial Exploring Psilocybin Therapy as a Treatment for Alcohol Use Disorder
